TUKYSA (tucatinib), FDA Approved for Treatment of Advanced Unresectable or Metastatic HER2-Positive Breast Cancer, Available at Biologics by McKesson

CARY, N.C.--()--Biologics by McKesson, an independent specialty pharmacy for oncology and other rare and complex therapeutic areas, has been selected by Seattle Genetics as a specialty pharmacy provider for TUKYSATM (tucatinib) for the treatment of HER2-positive breast cancer.

TUKYSA, approved by the FDA on April 17, 2020, is an orally bioavailable, small molecule tyrosine kinase inhibitor (TKI) that is highly selective for HER2, a growth factor receptor that is over-expressed in multiple cancers. This drug is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. On October 21, 2019, Seattle Genetics announced positive topline results from the HER2CLIMB trial evaluating tucatinib. The trial compared this therapy used in combination with trastuzumab and capecitabine to trastuzumab and capecitabine alone in patients who have locally advanced unresectable or metastatic HER2-positive breast cancer.

“We’re proud that Seattle Genetics has entrusted us to dispense this important therapy option for patients with metastatic HER2-positive breast cancer,” said Brandon Tom, vice president of Commercial Services at Biologics. “The addition of TUKYSA enables us to support providers across the various treatment options that exist for these patients.”

Biologics specialty pharmacy is committed to and recognized for its high level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes a pharmacist with in-depth knowledge of therapies, an experienced nurse, and a financial counselor who is familiar with various financial assistance programs and organizations that help patients. This highly-skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Life Sciences, a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

Contacts

McKesson
Claire Crye, Public Relations
281.825.9927 claire.crye@mckesson.com

Release Summary

Biologics by McKesson was selected as a specialty pharmacy provider for TUKYSA (tucatinib) for the treatment of HER2-positive breast cancer.

Contacts

McKesson
Claire Crye, Public Relations
281.825.9927 claire.crye@mckesson.com